{"id":"sy-3505-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL600550","moleculeType":"Small molecule","molecularWeight":"389.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, SY-3505 Capsules reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of how SY-3505 Capsules interacts with the SGLT2 receptor are not well understood.","oneSentence":"SY-3505 Capsules is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:44.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06254599","phase":"PHASE3","title":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":255},{"nctId":"NCT05869162","phase":"PHASE2","title":"Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI","status":"UNKNOWN","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2023-06-30","conditions":"Non-small-cell Lung Carcinoma","enrollment":153},{"nctId":"NCT05257512","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2020-04-26","conditions":"Non-small Cell Lung Cancer","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CT-3505; Ficonalkib"],"phase":"phase_3","status":"active","brandName":"SY-3505 Capsules","genericName":"SY-3505 Capsules","companyName":"Shouyao Holdings (Beijing) Co. LTD","companyId":"shouyao-holdings-beijing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SY-3505 Capsules is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}